COMMUNIQUÉS West-GlobeNewswire

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
30/07/2026
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio [...]
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
30/07/2026
Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial execution Harmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital, marking an [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
30/07/2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
PharmAla Issues Q3 Financial Statements and AGM Update
30/07/2026
TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in [...]
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
30/07/2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a [...]
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
30/07/2026
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab [...]
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
30/07/2026
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of [...]
MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients
30/07/2026
FDA-approved supplement advances early feasibility study (EFS) toward full enrollment JACKSONVILLE, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to [...]
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
30/07/2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second [...]
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
30/07/2026
As of July 29, 2026, trading volume on the Rain protocol reached $860MM 1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. ( [...]
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a [...]
CorVascular Launches ASUS Handheld Ultrasound Portfolio for Vascular Specialists at SVU 2026
30/07/2026
Exclusive U.S. Distributor to Showcase Live Demos of the FDA-Cleared Wireless LU800 Featuring Up to 2.5 Hours of Continuous Operation MINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- CorVascular today announced the [...]
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
30/07/2026
Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or [...]
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
30/07/2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR- [...]

Pages